Faruqi & Faruqi, LLP Investigates Savara Claims for Investors Facing Losses

Faruqi & Faruqi, LLP, a prominent national securities law firm, has announced its investigation into potential claims on behalf of investors of Savara Inc., particularly those who suffered losses during a defined period. Investors who acquired securities of Savara between March 7, 2024, and May 23, 2025, are encouraged to reach out to the firm to explore their legal rights and options.

Background on Savara's SEC Investigation

As outlined by James (Josh) Wilson, the partner at Faruqi & Faruqi, the investigation relates to allegations that Savara and its executives failed to comply with federal securities laws, thus misleading investors regarding critical information affecting the company’s operations. The complaint highlights that statements made by the company did not align with the reality of their Biologics License Application (BLA) for MOLBREEVI, a treatment aimed at patients suffering from autoimmune pulmonary alveolar proteinosis (PAP).

Allegations Against Savara

The core of the allegations indicates that key aspects of the application were inadequately addressed, leading to a refusal to file letter from the FDA concerning the approval of MOLBREEVI. The lack of sufficient data on chemistry, manufacturing, and controls raised red flags. Thus, it became less likely that Savara would maintain its commitment to a timeline for completing its BLA submission, significantly impacting investor trust and potential funding.

On May 27, 2025, Savara confirmed that it had received a refusal to file letter from the FDA, resulting in a sharp decline in the company's stock price—a drop of nearly 32%, closing at $1.94 per share. This marked a significant financial setback for many investors who relied on the company’s assurances about the approval process and its implications for revenue growth and capital needs.

Inviting Investor Participation

Faruqi & Faruqi aims to facilitate investors in evaluating their options, especially as the November 7, 2025, deadline approaches for individuals wishing to lead the plaintiffs' case in the ongoing federal class action against Savara. Investors are reminded that participation in this action does not limit their rights to recover any potential losses, regardless of leading the class or remaining an absent member.

Moreover, the firm invites anyone with information, including whistleblowers and former Savara employees, to come forward and share insights or support the ongoing investigation. The law office emphasizes that all communications will remain confidential, ensuring that the privacy and legal protections of individuals involved will be respected.

Conclusion

Faruqi & Faruqi remains steadfast in its mission to protect investors and ensure that those who may have suffered due to misleading corporate practices are heard. Investors who believe they could be entitled to recover losses from their Savara investments should not hesitate to contact Faruqi & Faruqi. The dedicated team is prepared to discuss individual circumstances and work towards justice for affected shareholders.

For more details about the ongoing class action or to contact the office directly, interested parties are encouraged to visit Faruqi & Faruqi's website or reach out through the specified lines, signaling a proactive step toward addressing the impact of Savara's alleged infringement.

Contact Information
Faruqi & Faruqi, LLP encourages those affected to communicate with partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) for personalized assistance and updates on the matter.